Karine Aouchiche, Camille Charmensat, Pertuit Morgane, Cécile Teinturier, Patricia Bretones, Aude Brac de la Perriere, Valérie Layet, Natacha Bouhours Nouet, Marie Christine Vantyghem, Elsa Haine, Marie-Laure Nunes-Sanchez, Odile Camart, Sabine Baron, Frederic Castinetti, Anne Barlier, Thierry Brue, Rachel Reynaud, Alexandru Saveanu
{"title":"Phenotype and genotype of 23 patients with hypopituitarism and pathogenic GLI2 variants.","authors":"Karine Aouchiche, Camille Charmensat, Pertuit Morgane, Cécile Teinturier, Patricia Bretones, Aude Brac de la Perriere, Valérie Layet, Natacha Bouhours Nouet, Marie Christine Vantyghem, Elsa Haine, Marie-Laure Nunes-Sanchez, Odile Camart, Sabine Baron, Frederic Castinetti, Anne Barlier, Thierry Brue, Rachel Reynaud, Alexandru Saveanu","doi":"10.1093/ejendo/lvaf015","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To analyze the phenotype and genotype of patients with congenital hypopituitarism and pathogenic GLI2 variants.</p><p><strong>Methods: </strong>A large cohort of patients with hypopituitarism was screened for GLI2 variants using a next-generation sequencing panel. Genotype-phenotype correlations were then assessed using GENHYPOPIT phenotypic data.</p><p><strong>Results: </strong>Of the 39 GLI2 variants identified in 717 index cases, 17 were classified as pathogenic or likely pathogenic. All these GLI2 variants were identified in 23 patients (17 index cases and 6 relatives) with associated pituitary stalk interruption syndrome or extrapituitary manifestations. GLI2 variants were the most frequent identified genetic cause in patients with syndromic hypopituitarism (68%): 88% (15/17) of mutations were truncating variants, and 45% were de novo. Most patients with a GLI2 variant (21/23, 91%) had hypopituitarism, including 21.7% (5/23) presenting isolated growth hormone deficiency. Two patients had Kallman syndrome. Pituitary morphological abnormalities were present in 84% of the patients with pathogenic GLI2 variants (index cases and affected relatives). The remaining signs included neurocognitive disorders (38%), hexadactyly (27%), cardiac septal defects and renal/vesical abnormalities. A possible digenic origin (GLI2/HESX1) is proposed in one family.</p><p><strong>Conclusion: </strong>In this large multicentric international cohort, GLI2 was the most frequently identified genetic cause of syndromic congenital hypopituitarism with constant association pituitary stalk interruption syndrome or extrapituitary clinical features. In addition to polydactyly and neurocognitive disorders, cardiac and renal abnormalities were also frequently observed and should be investigated further. The variable expression of GLI2-associated phenotypes justifies further research in this area.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":""},"PeriodicalIF":5.3000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ejendo/lvaf015","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To analyze the phenotype and genotype of patients with congenital hypopituitarism and pathogenic GLI2 variants.
Methods: A large cohort of patients with hypopituitarism was screened for GLI2 variants using a next-generation sequencing panel. Genotype-phenotype correlations were then assessed using GENHYPOPIT phenotypic data.
Results: Of the 39 GLI2 variants identified in 717 index cases, 17 were classified as pathogenic or likely pathogenic. All these GLI2 variants were identified in 23 patients (17 index cases and 6 relatives) with associated pituitary stalk interruption syndrome or extrapituitary manifestations. GLI2 variants were the most frequent identified genetic cause in patients with syndromic hypopituitarism (68%): 88% (15/17) of mutations were truncating variants, and 45% were de novo. Most patients with a GLI2 variant (21/23, 91%) had hypopituitarism, including 21.7% (5/23) presenting isolated growth hormone deficiency. Two patients had Kallman syndrome. Pituitary morphological abnormalities were present in 84% of the patients with pathogenic GLI2 variants (index cases and affected relatives). The remaining signs included neurocognitive disorders (38%), hexadactyly (27%), cardiac septal defects and renal/vesical abnormalities. A possible digenic origin (GLI2/HESX1) is proposed in one family.
Conclusion: In this large multicentric international cohort, GLI2 was the most frequently identified genetic cause of syndromic congenital hypopituitarism with constant association pituitary stalk interruption syndrome or extrapituitary clinical features. In addition to polydactyly and neurocognitive disorders, cardiac and renal abnormalities were also frequently observed and should be investigated further. The variable expression of GLI2-associated phenotypes justifies further research in this area.
期刊介绍:
European Journal of Endocrinology is the official journal of the European Society of Endocrinology. Its predecessor journal is Acta Endocrinologica.
The journal publishes high-quality original clinical and translational research papers and reviews in paediatric and adult endocrinology, as well as clinical practice guidelines, position statements and debates. Case reports will only be considered if they represent exceptional insights or advances in clinical endocrinology.
Topics covered include, but are not limited to, Adrenal and Steroid, Bone and Mineral Metabolism, Hormones and Cancer, Pituitary and Hypothalamus, Thyroid and Reproduction. In the field of Diabetes, Obesity and Metabolism we welcome manuscripts addressing endocrine mechanisms of disease and its complications, management of obesity/diabetes in the context of other endocrine conditions, or aspects of complex disease management. Reports may encompass natural history studies, mechanistic studies, or clinical trials.
Equal consideration is given to all manuscripts in English from any country.